Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with non-muscle invasive bladder cancer who were treated with 5-alpha reductase inhibitors had lower recurrence rates and higher recurrence-free survival rates compared to untreated patients.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.

This review discusses risk factors for intraoperative floppy iris syndrome, emphasizing tamsulosin and other α1 blockers, and underscores the importance of preoperative screening to mitigate surgical complications, but it reports no new results.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This review discusses the potential of 4-azasteroids as 5α-reductase inhibitors for treating hirsutism, reporting their promising effects in animal studies but noting no clinical trials have been conducted yet.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

In a reported case, the use of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, resulted in hair changes and acneiform eruptions as cutaneous side effects.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

In this case report, a 40-year-old woman with systemic lupus erythematosus developed Type B Insulin Resistance Syndrome, characterized by severe hyperglycemia despite high insulin doses, requiring immunosuppressive therapy to manage refractory symptoms.

Ritlecitinib works well and is safe for treating alopecia areata.

This review discusses drug repositioning for cardiometabolic disorders and reports no new clinical findings; the authors emphasize its potential benefits, such as known safety profiles and reduced development costs compared to new drug development.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

This Cochrane review reports that 5-alpha reductase inhibitors may slightly reduce urological symptoms and acute urinary retention risk compared to placebo, with a possible small reduction in surgical intervention need compared to alpha blockers.

In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.